Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period

CompletedOBSERVATIONAL
Enrollment

1,107

Participants

Timeline

Start Date

May 8, 2020

Primary Completion Date

June 25, 2020

Study Completion Date

June 25, 2020

Conditions
AnxietyDepressionCovid19CancerChronic Disease
Interventions
DIAGNOSTIC_TEST

Hospital Anxiety Depression Scale

HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).

Trial Locations (1)

34660

Sultan Abdülhamid Han Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey

OTHER

NCT04698044 - Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period | Biotech Hunter | Biotech Hunter